AstraZeneca (AZN) has raised its stake in Moderna Therapeutics. The British drug maker invested another $140M in the Moderna's preferred stock, raising its stake to 9%. The companies inked their original collaboration agreement in March 2013 with the aim of developing messenger RNA therapeutics for the treatment of cardiovascular, metabolic and renal diseases as well as certain cancers. They inked a new deal in January 2016 focused exclusively in oncology.